Escitalopram in the Long-term Treatment of Major Depressive Disorder

References

• Owens MJ, Knight DL, Nemeroff CB: Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50:345–350
   Google Scholar
• Burke WJ, Gergel I, Bose A: Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63:331–336
   Google Scholar
• Wade A, Lemming OM, Hedegaard KB: Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17:95–102
   Google Scholar
• Lepola UM, Loft H, Reines EH: Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18:211–217
   Google Scholar
• Stahl SM, Gergel I, Li D: Escitalopram in the treatment of panic disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003; 64:1322–1327
   Google Scholar
• Lader M, Stender K, B–rger V, Nil R: Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004; 19:241–248
   Google Scholar
• Davidson JR, Bose A, Korotzer A, Zheng H: Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004; 19:234–240
   Google Scholar
• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th revision (DSM-IV). Washington, D.C.: American Psychiatric Press, 1994
   Google Scholar
• Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ; World Federation of Societies of Biological Psychiatry (WFSBF) Task Force on Treatment Guidelines for Unipolar Depressive Disorders: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 2002; 3:69–86
   Google Scholar
• Roose SP: Compliance: The impact of adverse events and tolerability on the physician–s treatment decisions. Eur Neuropsychopharmacol 2003; 13(Suppl 3):S85–92
   Google Scholar
• Montgomery SA, –sberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382–389
   Google Scholar
• World Medical Association (WMA): Declaration of Helsinki: Ethical principles for medical research involving human subjects, 1964
   Google Scholar
• Keller MB, Kocsis JH, Thase ME, Gelenberg AJ, Rush AJ, Koran L, et al.: Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial. JAMA 1998; 280:1665–1672
   Google Scholar
• Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM: Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000; 61:276–281
   Google Scholar
• Hirschfeld RM: Long-term side effects of SSRIs: Sexual dysfunction and weight gain. J Clin Psychiatry 2003; 64(Suppl 18):20–24
   Google Scholar
• Benazzi F: Weight gain in depression remitted with antidepressants: Pharmacological or recovery effect? Psychother Psychosom 1998; 67:271–274
   Google Scholar
• Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al.: Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998; 50:97–108
   Google Scholar
• Valenstein M, Vijan S, Zeber JE, Boehm K, Buttar A: The costutility of screening for depression in primary care. Ann Intern Med 2001; 134:345–360
   Google Scholar
• Montgomery SA. Clinically relevant effect sizes in depression. Eur Neuropsychopharmacol 1994; 4:283–284
   Google Scholar